[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE419390T1 - Verfahren zur diagnose von bauchspeicheldrüsenkrebs - Google Patents

Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Info

Publication number
ATE419390T1
ATE419390T1 AT03799106T AT03799106T ATE419390T1 AT E419390 T1 ATE419390 T1 AT E419390T1 AT 03799106 T AT03799106 T AT 03799106T AT 03799106 T AT03799106 T AT 03799106T AT E419390 T1 ATE419390 T1 AT E419390T1
Authority
AT
Austria
Prior art keywords
pancreatic cancer
pnc
methods
diagnosis
cells
Prior art date
Application number
AT03799106T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE419390T1 publication Critical patent/ATE419390T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03799106T 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs ATE419390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41487202P 2002-09-30 2002-09-30
US45088903P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
ATE419390T1 true ATE419390T1 (de) 2009-01-15

Family

ID=32073343

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03799104T ATE419391T1 (de) 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
AT03799106T ATE419390T1 (de) 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03799104T ATE419391T1 (de) 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen

Country Status (10)

Country Link
US (3) US7601826B2 (de)
EP (3) EP1556518B1 (de)
JP (2) JP4679149B2 (de)
CN (1) CN1703524B (de)
AT (2) ATE419391T1 (de)
AU (2) AU2003260966A1 (de)
CA (2) CA2500472A1 (de)
DE (2) DE60325628D1 (de)
ES (1) ES2320443T3 (de)
WO (2) WO2004031411A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
EP1730279A2 (de) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 als therapeutisches ziel von prc und pdaca
US7939251B2 (en) * 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
CA2567350C (en) 2004-05-21 2018-06-12 John D. Shaughnessy Use of gene expression profiling to predict survival in cancer patient
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006038904A2 (en) * 2004-08-06 2006-04-13 Applera Corporation Method and compositions for treating diseases targeting e-cadherin
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE102004049897B4 (de) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
US20090215666A1 (en) * 2005-07-28 2009-08-27 Oncotherapy Science, Inc. Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
EP1934615B1 (de) * 2005-09-19 2014-06-04 Janssen Diagnostics, LLC Verfahren und materialien zur identifizierung des ursprungs eines karzinoms unbekannter primärer herkunft
CN101415440A (zh) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 治疗肺癌的方法
BRPI0708311A2 (pt) 2006-02-28 2011-05-24 Oncotherapy Science Inc métodos para danificar células usando funções efetoras de anticorpos anti-epha4
CN101438167A (zh) * 2006-03-02 2009-05-20 肿瘤疗法科学股份有限公司 利用reg4蛋白诊断胰腺癌症的方法
CN1904072B (zh) * 2006-07-28 2012-07-18 浙江大学 一组筛选胰腺导管腺癌的基因组合及应用
KR20090040391A (ko) * 2006-08-18 2009-04-23 온코세라피 사이언스 가부시키가이샤 Ｒｅｇ４ 또는 ｋｉａａ０１０１을 과발현하는 암의 예방 및 치료 기술
US7811778B2 (en) * 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
DK2140269T3 (da) 2007-03-27 2013-12-16 Immunovia Ab Proteinsignatur/markører til at detektere adenocarcinom
SG183717A1 (en) 2007-08-20 2012-09-27 Oncotherapy Science Inc Foxm1 peptide and medicinal agent comprising the same
AU2008290060B2 (en) 2007-08-20 2014-04-24 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
WO2010001585A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA2734979A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Syngr4 for target genes of cancer therapy and diagnosis
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2010057175A1 (en) * 2008-11-17 2010-05-20 Bioalliance C.V. Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same
TWI469791B (zh) * 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
DE102010043541B4 (de) * 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
EP3450459B1 (de) 2009-12-28 2021-05-26 OncoTherapy Science, Inc. Anti-cdh3-antikörper und verwendungen davon
JP2013518560A (ja) * 2010-02-03 2013-05-23 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｗｈｓｃ１およびｗｈｓｃ１ｌ１
EP3355057A3 (de) * 2010-06-01 2018-12-12 Metanomics Health GmbH Mittel und verfahren zur diagnose von bauchspeicheldrüsenkrebs bei einer person
US20120040861A1 (en) * 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic Cancer Biomarkers and Uses Thereof
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
KR101297336B1 (ko) 2011-03-30 2013-08-14 인하대학교 산학협력단 점액성 낭성종양 진단 장치
KR101223598B1 (ko) 2011-04-06 2013-01-22 인하대학교 산학협력단 췌장 상피내 종양 진단 시스템
JP6247218B2 (ja) * 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション 癌のバイオマーカー
WO2014189843A1 (en) 2013-05-20 2014-11-27 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
SG10201807838SA (en) * 2014-03-11 2018-10-30 Council Queensland Inst Medical Res Determining cancer aggressiveness, prognosis and responsiveness to treatment
WO2015171736A2 (en) * 2014-05-07 2015-11-12 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
ES2843829T3 (es) 2014-09-26 2021-07-20 Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz Nuevos métodos para la subtipificación y el tratamiento del cáncer
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
CN105017403B (zh) * 2015-07-09 2018-07-03 陈勇 胰腺癌相关多肽dap44单克隆抗体的制备及其应用
WO2017061523A1 (ja) 2015-10-08 2017-04-13 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１由来ペプチドおよびそれを含むワクチン
US11203615B2 (en) 2017-09-11 2021-12-21 National University Corporation Hokkaido University Cancer treatment drug
EP3508855A1 (de) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Verfahren zur auswahl von patienten und kit
KR102328654B1 (ko) * 2019-04-17 2021-11-19 한국원자력의학원 암의 예방 또는 치료용 약학 조성물
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN115074365B (zh) * 2022-06-28 2023-02-28 中国医学科学院北京协和医院 靶向GATM基因的sgRNA及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU7499198A (en) 1997-05-21 1998-12-11 Johns Hopkins University, The Gene expression profiles in normal and cancer cells
EP1038030A2 (de) 1997-12-15 2000-09-27 Abbott Laboratories Reagenzien und methoden geeignet zur detektion von pankrease-erkrankungen
US6262249B1 (en) 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6429302B1 (en) 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001009317A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Gene associe au cancer de l'estomac
EP1661996A1 (de) 1999-12-01 2006-05-31 Genentech, Inc. Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
WO2001055323A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
CA2469941A1 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP2006500946A (ja) 2002-09-30 2006-01-12 オンコセラピー・サイエンス株式会社 精巣精上皮腫の診断方法
CN101438167A (zh) * 2006-03-02 2009-05-20 肿瘤疗法科学股份有限公司 利用reg4蛋白诊断胰腺癌症的方法

Also Published As

Publication number Publication date
EP1549771B1 (de) 2008-12-31
US7601826B2 (en) 2009-10-13
JP4679149B2 (ja) 2011-04-27
US20060270619A1 (en) 2006-11-30
EP2009117A2 (de) 2008-12-31
AU2003263603A1 (en) 2004-04-23
JP2006500947A (ja) 2006-01-12
EP1556518A2 (de) 2005-07-27
US20120028262A1 (en) 2012-02-02
DE60325617D1 (de) 2009-02-12
EP1556518B1 (de) 2008-12-31
CN1703524A (zh) 2005-11-30
AU2003263603A8 (en) 2004-04-23
DE60325628D1 (de) 2009-02-12
WO2004031411A2 (en) 2004-04-15
EP2009117A3 (de) 2009-03-18
WO2004031412A2 (en) 2004-04-15
ATE419391T1 (de) 2009-01-15
US20100093629A1 (en) 2010-04-15
WO2004031411A3 (en) 2004-09-30
WO2004031412A3 (en) 2004-07-15
CA2500472A1 (en) 2004-04-15
JP2006500948A (ja) 2006-01-12
AU2003260966A8 (en) 2004-04-23
CN1703524B (zh) 2010-04-07
US7943730B2 (en) 2011-05-17
CA2500482A1 (en) 2004-04-15
AU2003260966A1 (en) 2004-04-23
ES2320443T3 (es) 2009-05-22
EP1549771A2 (de) 2005-07-06

Similar Documents

Publication Publication Date Title
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2004031410A3 (en) Method for diagnosing testicular seminomas
WO2006085684A3 (en) Method of diagnosing bladder cancer
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
AU2003213594A1 (en) Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
WO2004031414A3 (en) Method for diagnosing prostate cancer
DE602004004775D1 (de) Verfahren zur Diagnose von Leberfibrose.
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
DE602004027534D1 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
WO2005083118A3 (en) Pin-prc transition genes
WO2007013359A3 (en) Cancer related gene rasgef1a
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties